- Melanosis, neurocutaneous
- Neurocutaneous melanosis syndrome
- Neurocutaneous melanocytosis
News & Events
On this page
ORDR Co-Sponsored Conferences
2016 Rare Disease Day at NIH, Monday, February 29, 2016
Location: Building 10, Masur Auditorium, National Institutes of Health, Bethesda, MD
Description: The 2016 Rare Disease Day at NIH will take place on February 29. The event, sponsored by NCATS and the NIH Clinical Center, aims to raise awareness about rare diseases, the patients they affect and the research collaborations that are addressing rare disease challenges. The day will feature tours, posters and exhibits, and presentations.
2013 International Expert Meeting on Congenital Melanocytic Nevi (CMN) and Neurocutaneous Melanocytosis (NCM), Saturday, September 28, 2013 - Monday, September 30, 2013
Location: Marseille, France
Description: The goals of the meeting are to foster and enable the coordination of novel, interdisciplinary and international collaborations among participants. The leadership of major U.S. and European LCMN advocacy groups will attend the conference, to further refine the international initiatives established in 2011. These outcomes will continue making important contributions to the improvement of diagnosis and treatment for patients with this disfiguring and potentially life-threatening disease.
2011 International Expert Meeting for Large Congenital Melanocytic Nevi (LCMN) and Neurocutaneous Melanocytosis (NCM), Friday, May 06, 2011 - Saturday, May 07, 2011
Location: University of Tübingen, Germany
Description: The goals of this conference are to: (1) improve/broaden the knowledge and understanding of causes and cures of LCMN/NCM among those in attendance; (2) disseminate knowledge collected at the meeting to concerned people via a robust Internet presentation and conventional print forums; (3) accelerate the search for causes and cures of LCMN/NCM through improved interdisciplinary networking, recruitment for research projects currently under way, and brainstorming on future research subjects; and (4) improve treatment outcomes.